Metraipolis › archive › dc_951bf071c03c

Implications of Potential US FDA Approval of Psychedelics or Psychedelic-Adjacents Such as Ibogaine for Pharmacy in Japan — Europe PMC PMID:42733721

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42733721
DOI
10.7759/cureus.116178
License (as archived)
solo-consultazione
Archived
2026-10-07T11:43:05.307Z
SHA-256 of the archived text
69677dd6c323d15e05ab4e90d595e5ba89720097c1aa57251ba5b0bf70d201c7
Stable URL of this page
https://metraipolis.com/documento/dc_951bf071c03c

How to cite

Implications of Potential US FDA Approval of Psychedelics or Psychedelic-Adjacents Such as Ibogaine for Pharmacy in Japan — Europe PMC PMID:42733721 — Europe PMC (en), https://europepmc.org/article/MED/42733721 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_951bf071c03c (Metraipolis archive dc_951bf071c03c, sha256 69677dd6c323d15e05ab4e90d595e5ba89720097c1aa57251ba5b0bf70d201c7)
BibTeX
@misc{dc951bf071c03c,
  title = {Implications of Potential US FDA Approval of Psychedelics or Psychedelic-Adjacents Such as Ibogaine for Pharmacy in Japan — Europe PMC PMID:42733721},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42733721},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_951bf071c03c; sha256 69677dd6c323d15e05ab4e90d595e5ba89720097c1aa57251ba5b0bf70d201c7},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42733721. Agents can read the archived copy with the MCP tool read_document.